AstraZeneca Invests $2 Billion in Summit Therapeutics to Advance Oncology Pipeline

Key Facts

1AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics to accelerate the development of ivonescimab.

AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics to accelerate the development of ivonescimab. Zacks reported that the investment is intended to expand the existing oncology collaboration between the two pharmaceutical firms.

AZN was trading at $164.12 on September 29, 2026, with a session high of $166.465 and a low of $163.24. This price activity follows the announcement of the capital injection aimed at validating and expanding the strategic partnership.